{"id":"NCT05513053","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","officialTitle":"Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-27","primaryCompletion":"2023-10-27","completion":"2023-10-27","firstPosted":"2022-08-23","resultsPosted":"2024-05-30","lastUpdate":"2025-09-09"},"enrollment":1308,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza Immunization"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH","otherNames":["Supemtek / Flublok Quadrivalent"]}],"arms":[{"label":"Group 9 to 17 years old","type":"EXPERIMENTAL"},{"label":"Group 18 to 49 years old","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile of RIV4 in all participants.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) Against Influenza Vaccine Antibodies at Day 29","timeFrame":"Day 29","effectByArm":[{"arm":"Cohort 1: Participants Aged 9 to 17 Years","deltaMin":1946,"sd":null},{"arm":"Cohort 2: Participants Aged 18 to 49 Years","deltaMin":982,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":35,"countries":["United States","Czechia","Poland","Spain"]},"refs":{"pmids":["40412421"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25371&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":641},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Chills"]}}